Myocardial effects of endothelin-1;Efeitos miocárdicos da endotelina-1

Revista Portuguesa de Cardiologia

Volumn 27, Issue 7-8, 2008, Pages 925-951

  Brás Silva, Carmen ^a,b   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Endothelin 1; Endothelium; ETA receptors; ETB receptors; Heart; Inotropy; Lusitropy; Myocardium

Indexed keywords

4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; ADRENOMEDULLIN; ANGIOTENSIN II; BOSENTAN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; GHRELIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROHORMONE; NORADRENALIN; PROSTAGLANDIN; RELAXIN; SEROTONIN;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CELL GROWTH; CORONARY ARTERY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME METABOLISM; HEART MUSCLE; HEART RATE; HEART RHYTHM; HUMAN; HYPERTROPHY; INOTROPISM; NONHUMAN; PRENATAL DEVELOPMENT; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; VASOCONSTRICTION;

BLOOD VESSELS; DIASTOLE; ENDOTHELIN-1; HEART; HUMANS; RECEPTORS, ENDOTHELIN;

EID: 53549132501     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (177)

1. Brutsaert DL. Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity. Physiol Rev 2003; 83: 59-115.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
3. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985; 248: C550-C556.
4. Gillespie MN, Owasoyo JO, McMurtry IF, O'Brien RF. Sustained coronary vasoconstriction provoked by a peptidergic substance released from endothelial cells in culture. J Pharmacol Exp Ther 1986; 236: 339-343.
5. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-415.
6. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989; 86: 2863-2867.
7. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. The human preproendothelin gene. Complete nucleotide sequence and regulation of expression. J Biol Chem 1989; 264: 14954-14959.
8. Saida K, Mitsui Y, Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J Biol Chem 1989; 264: 14613-14616.
9. Bloch KD, Hong CC, Eddy RL, Shows TB, Quertermous T. cDNA cloning and chromosomal assignment of the endothelin 2 gene: vasoactive intestinal contractor peptide is rat endothelin 2. Genomics 1991; 10: 236-42.
10. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730-732.
11. Sakurai T, Yanagisawa M, Takuwa Y et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
12. Vanhoutte PM. Endothelin-1 - a matter of life and breath. Nature 1994; 368: 693-694.
13. Ihara M, Ishikawa K, Fukuroda T et al. In vitro biological profile of a highly potent novel endothelin (ET) antagonist BQ-123 selective for the ETA receptor. J Cardiovasc Pharmacol 1992; 20: S11-S14.
14. Clozel M, Breu V, Burri K et al. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 1993; 365: 759-761.
15. Clozel M, Breu V, Gray GA et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-235.
16. Schmidt M, Kroger B, Jacob E et al. Molecular characterization of human and bovine endothelin converting enzyme (ECE-1). FEBS Lett 1994; 356: 238-243.
17. Shimada K, Takahashi M, Tanzawa K. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J Biol Chem 1994; 269: 18275-18278.
18. Xu D, Emoto N, Giaid A et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994; 78: 473-485.
19. Emoto N, Yanagisawa M. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J Biol Chem 1995; 270: 15262-15268.
20. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
21. D'Orleans-Juste P, Plante M, Honore JC, Carrier E, Labonte J. Synthesis and degradation of endothelin-1. Can J Physiol Pharmacol 2003; 81: 503-510.
22. Davenport AP, Maguire JJ. Endothelin. Handb Exp Pharmacol 2006; 176: 295-329.
23. Russell FD, Skepper JN, Davenport AP. Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. J Cardiovasc Pharmacol 1998; 31: 424-430.
24. Brunner F, Brás-Silva C, Cerdeira AS, Leite-Moreira AF. Cardiovascular endothelins: essential regulators of cardiovascular homeostasis. Pharmacol Ther 2006; 111: 508-531.
25. Neylon CB, Hoyland J, Mason WT, Irvine RF. Spatial dynamics of intracellular calcium in agonist-stimulated vascular smooth muscle cells. Am J Physiol 1990; 259: C675-C686.
26. Battistini B, D'Orleans-Juste P, Sirois P. Endothelins - circulating plasma levels and presence in other biologic fluids. Lab Invest 1993; 68: 600-628.
27. Wagner OF, Christ G, Wojta J et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992; 267: 16066-16068.
28. Brunner F. Tissue endothelin-1 levels in perfused rat heart following stimulation with agonists and in ischaemia and reperfusion. J Mol Cell Cardiol 1995; 27: 1953-1963.
29. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993; 268: 19126-19133.
30. Lecoin L, Sakurai T, Ngo MT, Abe Y, Yanagisawa M, Le Douarin NM. Cloning and characterization of a novel endothelin receptor subtype in the avian class. Proc Natl Acad Sci U S A 1998; 95: 3024-3029.
31. Davenport AP. International Union of Pharmacology. XXIX. Update on Endothelin Receptor Nomenclature. Pharmacol Rev 2002; 54: 219-226.
32. Sakurai T, Yanagisawa M, Masaki T. Molecular characterization of endothelin receptors. Trends Pharmacol Sci 1992; 13: 103-108.
33. Shraga-Levine Z, Sokolovsky M. Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific. Cell Mol Neurobiol 2000; 20: 305-317.
34. Miyauchi T, Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999; 61: 391-415.
35. Tsukahara H, Ende H, Magazine HI, Bahou WF, Goligorsky MS. Molecular and functional characterization of the non-isopeptide-selective ETB receptor in endothelial cells. Receptor coupling to nitric oxide synthase. J Biol Chem 1994; 269: 21778-21785.
36. De Nucci G, Thomas R, D'Orleans-Juste P et al. Pressor effects of circulating endothelin are limited by its removal in the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci U S A 1988; 85: 9797-9800.
37. Mallat A, Fouassier L, Preaux AM et al. Growth inhibitory properties of endothelin-1 in human hepatic myofibroblastic Ito cells. An endothelin B receptor-mediated pathway. J Clin Invest 1995; 96: 42-49.
38. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. Endothelin-induced apoptosis of A375 human melanoma cells. J Biol Chem 1998; 273: 12584-12592.
39. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994; 199: 1461-1465.
40. Honore JC, Fecteau MH, Brochu I, Labonte J, Bkaily G, D'Orleans-Juste P. Concomitant antagonism of endothelial and vascular smooth muscle cell-ETB receptors for endothelin induces hypertension in the hamster. Am J Physiol Heart Circ Physiol 2005; 289: H1258-H1264.
41. Ozaki S, Ohwaki K, Ihara M, Fukuroda T, Ishikawa K, Yano M. ETB-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells. Biochem Biophys Res Commun 1995; 209: 483-489.
42. Sudjarwo SA, Hori M, Tanaka T, Matsuda Y, Okada T, Karaki H. Subtypes of endothelin ETA and ETB receptors mediating venous smooth muscle contraction. Biochem Biophys Res Commun 1994; 200: 627-633.
43. Douglas SA, Meek TD, Ohlstein EH. Novel receptor antagonists welcome a new era in endothelin biology. Trends Pharmacol Sci 1994; 15: 313-316.
44. Leite-Moreira AF, Brás-Silva C. Inotropic effects of ETB receptor stimulation and their modulation by endocardial endothelium, NO, and prostaglandins. Am J Physiol Heart Circ Physiol 2004; 287: H1194-H1199.
45. Clozel M, Gray GA. Are there different ETB receptors mediating constriction and relaxation? J Cardiovasc Pharmacol 1995; 26: S262-S264.
46. Fukuroda T, Ozaki S, Ihara M et al. Necessity of dual blockade of endothelin ETA and ETB receptor subtypes for antagonism of endothelin-1-induced contraction in human bronchi. Br J Pharmacol 1996; 117: 995-999.
47. Mickley EJ, Gray GA, Webb DJ. Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol 1997; 120: 1376-1382.
48. Himeno A, Shigematsu K, Taguchi T, Niwa M. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: interaction in the recognition of endothelin-1 between ETA and ETB receptors. Cell Mol Neurobiol 1998; 18: 447-452.
49. Zuccarello M, Boccaletti R, Rapoport RM. Endothelin ET(B1) receptor-mediated relaxation of rabbit basilar artery. Eur J Pharmacol 1998; 357: 67-71.
50. Adner M, Shankley N, Edvinsson L. Evidence that ET-1, but not ET-3 and S6b, ET(A)-receptor mediated contractions in isolated rat mesenteric arteries are modulated by co-activation of ET(B) receptors. Br J Pharmacol 2001; 133: 927-935.
51. Harada N, Himeno A, Shigematsu K, Sumikawa K, Niwa M. Endothelin-1 binding to endothelin receptors in the rat anterior pituitary gland: possible formation of an ETA-ETB receptor heterodimer. Cell Mol Neurobiol 2002; 22: 207-226.
52. Gregan B, Jurgensen J, Papsdorf G et al. Ligand-dependent differences in the internalization of endothelin A and endothelin B receptor heterodimers. J Biol Chem 2004; 279: 27679-27687.
53. Gregan B, Schaefer M, Rosenthal W, Oksche A. Fluorescence resonance energy transfer analysis reveals the existence of endothelin-A and endothelin-B receptor homodimers. J Cardiovasc Pharmacol 2004; 44: S30-S33.
54. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J Appl Physiol 1996; 81: 1510-1515.
55. Dupuis J, Schwab AJ, Simard A, Cernacek P, Stewart DJ, Goresky CA. Kinetics of endothelin-1 binding in the dog liver microcirculation in vivo. Am J Physiol 1999; 277: G905-G914.
56. Johnstrom P, Fryer TD, Richards HK, Harris NG, Barret O, Clark JC. Positron emission tomography using 18F-labelled endothelin-1 reveals prevention of binding to cardiac receptors owing to tissue-specific clearance by ETB receptors in vivo. Br J Pharmacol 2005; 144: 115-122.
57. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990; 265: 14150-14155.
58. Turner AJ, Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997; 11: 355-364.
59. Abe Y, Nakayama K, Yamanaka A, Sakurai T, Goto K. Subtype-specific trafficking of endothelin receptors. J Biol Chem 2000; 275: 8664-8671.
60. Bremnes T, Paasche JD, Mehlum A, Sandberg C, Bremnes B, Attramadal H. Regulation and intracellular trafficking pathways of the endothelin receptors. J Biol Chem 2000; 275: 17596-17604.
61. Oksche A, Boese G, Horstmeyer A et al. Late endosomal/lysosomal targeting and lack of recycling of the ligand-occupied endothelin B receptor. Mol Pharmacol 2000; 57: 1104-1113.
62. Yamaguchi T, Murata Y, Fujiyoshi Y, Doi T. Regulated interaction of endothelin B receptor with caveolin-1. Eur J Biochem 2003; 270: 1816-1827.
63. Boivin B, Villeneuve LR, Farhat N, Chevalier D, Allen BG. Sub-cellular distribution of endothelin signaling pathway components in ventricular myocytes and heart: lack of preformed caveolar signalosomes. J Mol Cell Cardiol 2005; 38: 665-676.
64. Masaki T. Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 1995; 35: 235-255.
65. Sato K, Oka M, Hasunuma K, Ohnishi M, Sato K, Kira S. Effects of separate and combined ETA and ETB blockade on ET-1-induced constriction in perfused rat lungs. Am J Physiol 1995; 269: L668-L672.
66. Davie N, Haleen SJ, Upton PD, Polak JM, Yacoub MH. Morrell NW, Wharton J. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002; 165: 398-405.
67. Moreland S, McMullen DM, Delaney CL, Lee VG, Hunt JT. Venous smooth muscle contains vasoconstrictor ETB-like receptors. Biochem Biophys Res Commun 1992; 184: 100-106.
68. Bacon CR, Davenport AP. Endothelin receptors in human coronary artery and aorta. Br J Pharmacol 1996; 117: 986-992.
69. Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol 2005; 43: 19-29.
70. Warner TD. Relationships between the endothelin and nitric oxide pathways. Clin Exp Pharmacol Physiol 1999; 26: 247-252.
71. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. Heart Fail Rev 2003; 8: 107-115.
72. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr. Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. Hypertension 1998; 32: 917-922.
73. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist - Attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-kB. Circ Res 2003; 92: 32-40.
74. Wiley KE, Davenport AP. Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1146-1152.
75. Nakashima M, Vanhoutte PM. Endothelin-1 and -3 cause endothelium- dependent hyperpolarization in the rat mesenteric artery. Am J Physiol 1993; 265: H2137-H2141.
76. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992; 20: 292-297.
77. Yang ZH, Richard V, von Segesser L et al. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation 1990; 82: 188-195.
78. Marini M, Carpi S, Bellini A, Patalano F, Mattoli S. Endothelin-1 induces increased fibronectin expression in human bronchial epithelial cells. Biochem Biophys Res Commun 1996; 220: 896-899.
79. Hafizi S, Allen SP, Goodwin AT, Chester AH, Yacoub MH. Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis 1999; 146: 351-359.
80. Xu SW, Howat SL, Renzoni EA et al. Endothelin-1 induces expression of matrix-associated genes in lung fibroblasts through MEK/ERK. J Biol Chem 2004; 279: 23098-23103.
81. Zouki C, Baron C, Fournier A, Filep JG. Endothelin-1 enhances neutrophil adhesion to human coronary artery endothelial cells: role of ET(A) receptors and platelet-activating factor. Br J Pharmacol 1999; 127: 969-979.
82. Weissberg PL, Witchell C, Davenport AP, Hesketh TR, Metcalfe JC. The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis 1990; 85: 257-262.
83. Matsuura A, Yamochi W, Hirata K, Kawashima S, Yokoyama M. Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 1998; 32: 89-95.
84. Schiffrin EL, Touyz RM. Vascular biology of endothelin. J Cardiovasc Pharmacol 1998; 32 Suppl 3: S2-13.
85. Takanashi M, Endoh M. Characterization of positive inotropic effect of endothelin on mammalian ventricular myocardium. Am J Physiol 1991; 261: H611-H619.
86. Leite-Moreira AF, Brás-Silva C, Pedrosa CA, Rocha-Sousa AA. ET1 increases distensibility of acutely loaded myocardium: a novel ETA and Na+/H+ exchanger-mediated effect. Am J Physiol Heart Circ Physiol 2003; 284: H1332-H1339.
87. Wang J, Paik G, Morgan JP. Endothelin 1 enhances myofilament Ca2+ responsiveness in aequorin-loaded ferret myocardium. Circ Res 1991; 69: 582-589.
88. Meyer M, Lehnart S, Pieske B et al. Influence of endothelin-1 on human atrial myocardium-myocardial function and subcellular pathways. Basic Res Cardiol 1996; 91: 86-93.
89. Baydoun AR, Peers S, Cirino G, Woodward B. Effects of endothelin-1 on the rat isolated heart. J Cardiovasc Pharmacol 1989; 13: S193-S196.
90. Pieske B, Beyermann B, Breu V et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and fading myocardium. Circulation 1999; 99: 1802-1809.
91. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart - Studies with an intracoronary ETA receptor antagonist. Circulation 2000; 101: 142-147.
92. Izumi M, Miyamoto S, Hori M, Ozaki H, Karaki H. Negative inotropic effect of endothelin-1 in the mouse right ventricle. Eur J Pharmacol 2000; 396: 109-117.
93. Zhu Y, Yang HT, Endoh M. Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle. Am J Physiol 1997; 42: H119-H127.
94. Chu L, Takahashi R, Norota I et al. Signal transduction and Ca2+ signaling in contractile regulation induced by crosstalk between endothelin-1 and norepinephrine in dog ventricular myocardium. Circ Res 2003; 92: 1024-1032.
95. Molenaar P, O'Reilly G, Sharkey A et al. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res 1993; 72: 526-538.
96. Kelso EJ, McDermott BJ, Silke B, Spiers JP. Endothelin A receptor subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes isolated from rabbit myocardium. J Pharmacol Exp Ther 2000; 294: 1047-1052.
97. Beyer ME, Slesak G, Hoffmeister HM. Significance of endothelin B receptors for myocardial contractility and myocardial energy metabolism. J Pharmacol Exp Ther 1996; 278: 1228-1234.
98. Beyer ME, Slesak G, Hovelborn T, Kazmaier S, Nerz S, Hoffmeister HM. Inotropic effects of endothelin-1 - Interaction with molsidomine and with BQ 610. Hypertension 1999; 33: 145-152.
99. Piuhola J, Makinen M, Szokody I, Ruskoaho H. Dual role of endothelin-1 via ETA and ETB receptors in regulation of cardiac contractile function in mice. Am J Physiol Heart Circ Physiol 2003; 285: H112-H118.
100. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB 209670. J Pharmacol Exp Ther 2000; 292: 449-459.
101. Brás-Silva C, Fontes-Sousa A, Moura C, Areias JC, Leite-Moreira AF. Impaired response to ETB receptor stimulation in heart failure. Functional evidence of endocardial endothelial dysfunction? Exp Biol Med 2006; 231: 893-898.
102. Sugden PH. An overview of endothelin signaling in the cardiac myocyte. J Mol Cell Cardiol 2003; 35: 871-886.
103. Kramer BK, Smith TW, Kelly RA. Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger. Circ Res 1991; 68: 269-279.
104. Katoh H, Terada H, Iimuro M et al. Heterogeneity and underlying mechanism for inotropic action of endothelin-1 in rat ventricular myocytes. Br J Pharmacol 1998; 123: 1343-1350.
105. Woo SH, Lee CO. Effects of endothehn-1 on Ca2+ signaling in guinea-pig ventricular myocytes: role of protein kinase C. J Mol Cell Cardiol 1999; 31: 631-643.
106. Ponicke K, Vogelsang M, Heinroth M et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998;97:744-751.
107. Dhein S, Giessler C, Wangemann T, Silber RE, Zerkowski HR, Brodde OE. Differential pattern of endothelin-1-induced inotropic effects in right atria and left ventricles of the human heart. J Cardiovasc Pharmacol 2000; 36: 564-569.
108. Garjani A, Wainwright CL, Zeitlin IJ, Wilson C, Slee SJ. Effects of endothelin-1 and the ETA-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats. J Cardiovasc Pharmacol 1995; 25: 634-642.
109. Sharif I, Kane KA, Wainwright CL. Endothelin and ischaemic arrhythmias - antiarrhythmic or arrhythmogenic? Cardiovasc Res 1998; 39: 625-632.
110. Brunner F, Opie LH. Role of endothelin-A receptors in ischemic contracture and reperfusion injury. Circulation 1998; 97: 391-398.
111. Tanaka H, Habuchi Y, Yamamoto T, Nishio M, Morikawa J, Yoshimura M. Negative chronotropic actions of endothelin-1 on rabbit sinoatrial node pacemaker cells. Br J Pharmacol 1997; 122: 321-329.
112. Ono K, Tsujimoto G, Sakamoto A et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature 1994; 370: 301-304.
113. Kim D. Endothelin activation of an inwardly rectifying K+ current in atrial cells. Circ Res 1991; 69: 250-255.
114. James AF, Xie LH, Fujitani Y, Hayashi S, Horie M. Inhibition of the cardiac protein kinase A-dependent chloride conductance by endothelin-1. Nature 1994; 370: 297-300.
115. Parmley WW, Chuck L. Length-dependent changes in myocardial contractile state. Am J Physiol 1973; 224: 1195-1199.
116. Cingolani HE, Perez NG, Aiello EA, de Hurtado MC. Intracellular signaling following myocardial stretch: an autocrine/paracrine loop. Regul Pept 2005; 128: 211-220.
117. Perez NG. Camihon de Hurtado MC, Cingolani HE. Reverse mode of the Na+-Ca2+ exchange after myocardial stretch - Underlying mechanism of the slow force response. Circ Res 2001; 88: 376-382.
118. Ennis IL, Garciarena CD, Pérez NG, Dulce RA, Camilión de Hurtado MC, Cingolani HE. Endothelin isoforms and the response to myocardial stretch. Am J Physiol Heart Circ Physiol 2005; 288: H2925-H2930.
119. Piuhola J, Szokodi I, Kinnunen P et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 2003; 41: 93-98.
120. Gillebert TC, Leite-Moreira AF, De Hert SG. Load dependent diastolic dysfunction in heart failure. Heart Failure Rev 2000; 5: 345-355.
121. Kass DA, Bronzwaer JG, Paulus WJ. What mechanisms underlie diastolic dysfunction in heart failure? Circ Res 2004; 94: 1533-1542.
122. Leite-Moreira AF. Current perspectives in diastolic dysfunction and diastolic heart failure. Heart 2006; 92: 712-718.
123. Li K, Stewart DJ, Rouleau JL. Myocardial contractile actions of endothelin-1 in rat and rabbit papillary muscles. Circ Res 1991; 69: 301-312.
124. Ezra D, Goldstein RE, Czaja JF, Feuerstein GZ. Lethal ischemia due to intracoronary endothelin in pigs. Am J Physiol 1989; 257: H339-H343.
125. Karwatowska-Prokopczuk E, Wennmalm A. Effects of endothelin on coronary flow, mechanical performance, oxygen uptake, and formation of purines and on outflow of prostacyclin in the isolated rabbit heart. Circ Res 1990; 66: 46-54.
126. Leite-Moreira AF, Gillebert TC. Nonuniform course of left ventricular pressure fall and its regulation by load and contractile state. Circulation 1994; 90: 2481-2491.
127. Leite-Moreira AF, Correia-Pinto J, Gillebert TC. Afterload induced changes in myocardial relaxation: A mechanism for diastolic relaxation. Cardiovasc Res 1999; 43: 344-353.
128. Brown RD, Ambler SK, Mitchell MD, Long CS. The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Ann Rev Pharmacol Toxicol 2005; 45: 657-687.
129. Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005; 37: 2-12.
130. Tsuruda T, Costello-Boerrigter LC, Burnett JC Jr. Matrix metalloproteinases: pathways of induction by bioactive molecules. Heart Fail Rev 2004; 9: 53-61.
131. Clozel JP, Clozel M. Effects of endothelin on the coronary vascular beds in open chest dogs. Circ Res 1989; 65: 1193-1200.
132. Horn GJ, Touhey B, Rubanyi GM. Effects of intracoronary administration of endothelin in anesthetized dogs: comparison with Bay k 8644 and U 48619. J Cardiovasc Pharmacol 1992; 19: 194-200.
133. Khandoudi N, Ho J, Karmazyn M. Role of Na(+)-H+ exchange in mediating effects of endothelin-1 on normal and ischemic/reperfused hearts. Circ Res 1994; 75: 369-378.
134. Offstad J, Tonnessen T, Kirkeboen KA, Ilebekk A, Downing SE. Modulation of systolic and diastolic function by endothelin-1: relation to coronary flow. Acta Physiol Scand 1995; 154: 103-111.
135. Grossman W, Barry WH. Diastolic pressure-volume relations in the diseased heart. Fed Proc 1980; 39: 148-155.
136. Paulus WJ, Grossmann W, Serizawa T, Bourdillon PD, Pasipoularides A, Mirsky I. Different effects of two types of ischemia on myocardial systolic and diastolic function. Am J Physiol 1985; 248: H719-H728.
137. Leite-Moreira AF, Correia-Pinto J. Load as an acute determinant of end-diastolic pressure-volume relation. Am J Physiol Heart Circ Physiol 2001; 280: H51-H59.
138. Brás-Silva C, Leite-Moreira AF. Obligatory role of the endocardial endothelium in the increase of myocardial distensibility induced by endothelin-1. Exp Biol Med 2006; 231: 876-881.
139. Brás-Silva C, Monteiro-Sousa D, Duarte AJ et al. Nitric oxide and prostaglandins - important players in endothelin-1 induced myocardial distensibility. Physiol Res 2007 May 30: (Epub ahead of print).
140. Shubeita HE, McDonough PM, Harris AN et al. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 1990; 265: 20555-20562.
141. Ito H. Endothelins and cardiac hypertrophy. Life Sci 1997; 61: 585-593.
142. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: mechanisms and signal transduction pathways. Cardiovasc Res 2000; 47: 23-37.
143. Arai M, Yoguchi A, Iso T et al. Endothelin-1 and its binding sites are upregulated in pressure overload cardiac hypertrophy. Am J Physiol 1995; 268: H2084-H2091.
144. Ito H, Hiroe M, Hirata Y et al. Endothelin ETA receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 1994; 89: 2198-2203.
145. Schunkert H, Orzechowski HD, Bocker W, Meier R, Riegger GA, Paul M. The cardiac endothelin system in established pressure overload left ventricular hypertrophy. J Mol Med 1999; 77: 623-630.
146. Iwanaga Y, Kihara Y, Hasegawa K, Inagaki K, Yoneda T, Kaburagi S, Araki M, Sasayama S. Cardiac endothelin-1 plays a critical role in the functional deterioration of left ventricles during the transition from compensatory hypertrophy to congestive heart failure in salt-sensitive hypertensive rats. Circulation 1998; 98: 2065-2073.
147. Miyauchi T, Yorikane R, Sakai S et al. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ Res 1993; 73: 887-897.
148. Brown LA, Nunez DJ, Brookes CI, Wilkins MR. Selective increase in endothelin-1 and endothelin A receptor subtype in the hypertrophied myocardium of the aorto-venacaval fistula rat. Cardiovasc Res 1995; 29; 768-774.
149. Ichikawa KI, Hidai C, Okuda C et al. Endogenous endothelin-1 mediates cardiac hypertrophy and switching of myosin heavy chain gene expression in rat ventricular myocardium. J Am Coll Cardiol 1996; 27: 1286-1291.
150. Brunner F, Wolkart G, Haleen S. Defective intracellular calcium handling in monocrotaline-induced right ventricular hypertrophy: protective effect of long-term endothelin-A receptor blockade with 2-benzo[q,3]dioxol-5-yl-3-benzyl- 4-(4-methoxy-phenyl-)-4-oxobut-2-enoate-sodium (PD155080). J Pharmacol Exp Ther 2002; 300: 442-449.
151. Chen SJ, Chen YF, Meng QC, Durand J, Dicarlo VS, Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995; 79: 2122-2131.
152. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995; 268: H828-H835.
153. HiU NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997; 83: 1209-1215.
154. Jasmin JF, Lucas M, Cernacek P, Dupuis J. Effectiveness of a nonselective ET(A/B) and a selective ET(A) antagonist in rats with monocrotaline-induced pulmonary hypertension. Circulation 2001; 103: 314-318.
155. Yuyama H, Fujimori A, Sanagi M et al. The orally active nonpeptide selective endothelin ETA receptor antagonist YM598 prevents and reverses the development of pulmonary hypertension in monocrotaline-treated rats. Eur J Pharmacol 2004; 496: 129-139.
156. Sharma S, Taegtmeyer H, Adrogue J et al. Dynamic changes of gene expression in hypoxia-induced right ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2004; 286: H1185-H1192.
157. Schott P, Singer SS, Kogler H et al. Pressure overload and neurohumoral activation differentially affect the myocardial proteome. Proteomics 2005; 5: 1372-1381.
158. Lourenço AP, Roncon-Albuquerque Jr R, Brás-Silva C et al. Myocardial dysfunction and neurohumoral activation without remodeling in the left ventricle of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 2006; 291: H1587-H1594.
159. Cullen JP, Bell D, Kelso EJ, McDermott BJ. Use of A-192621 to provide evidence for involvement of endothelin ETB-receptors in endothelin-1-mediated cardiomyocyte hypertrophy. Eur J Pharmacol 2001; 417: 157-168.
160. Lee GR, Bell D, Kelso EJ, Argent CC, McDermott BJ. for altered ETB receptor characteristics during development and progression of ventricular cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol 2004; 287, H425-H432.
161. Wang J, Morgan JP. Endothelin reverses the effects of acidosis on the intracellular Ca2+ transient and contractility in ferret myocardium. Circ Res 1992; 71: 631-639.
162. Mebazaa A, Wetzel R, Cherian M, Abraham M. Comparison between endocardial and great vessel endothelial cells: morphology, growth, and prostaglandin release. Am J Physiol 1995; 268: H250-H259.
163. Prendergast BD, Anning PB, Lewis MJ, Shah AM. Regulation of left ventricular relaxation in the isolated guinea-pig heart by endogenous endothelin. Cardiovasc Res 1997; 33: 131-138.
164. Brutsaert DL, Meulemans AL, Sipido KR, Sys SU. Effects of damaging the endocardial surface on the mechanical performance of isolated cardiac muscle. Circ Res 1988; 62: 358-366.
165. Evans HG, Lewis MJ, Shah AM. Modulation of myocardial relaxation by basal release of endothelin from endocardial endothelium. Cardiovasc Res 1994; 28: 1694-1699.
166. Shah AM. Decreased myocardial contractility after damage to endocardial endothelium is caused mainly by loss of endothelin production. Cardiovasc Res 1995; 30: 644-645.
167. Talukder MA, Norota I, Sakurai K, Endoh M. Inotropic response of rabbit ventricular myocytes to endothelin-1: difference from isolated papillary muscles. Am J Physiol Heart Circ Physiol 2001; 281: H596-H605.
168. De Keulenaer GW, Andries LJ, Sys SU, Brutsaert DL. Endothelin-mediated positive inotropic effect induced by reactive oxygen species in isolated cardiac muscle. Circ Res 1995; 76: 878-884.
169. Frehn C, Guedin D. Why are circulating concentrations of endothelin-1 so low? Cardiovasc Res 1994; 28: 1613-1622.
170. Nishimura T, Yamada H, Kinoshita M, Ochi J. Endothelin expression during rat heart development: an immunohistochemical and in situ hybridization study. Biomed Res 1994; 15: 291-298.
171. Lariviere R, Deng LY, Day R, Sventek P, Thibault G, Schiffrin EL. Increased endothelin-1 gene expression in the endothelium of coronary arteries and endocardium in the DOCA-salt hypertensive rat. J Mol Cell Cardiol 1995; 27: 2123-2131.
172. Morimoto T, Hasegawa K, Kaburagi S et al. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 2000; 275: 13721-13726.
173. Kurihara Y, Kurihara H, Suzuki H et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature. 1994; 368: 703-710.
174. Kurihara Y, Kurihara H, Oda H et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest. 1995; 96: 293-300.
175. Kanzawa N, Poma CP, Takebayashi-Suzuki K, Diaz KG, Layliev J, Mikawa T. Competency of embryonic cardiomyocytes to undergo Purkinje fiber differentiation is regulated by endothelin receptor expression. Development 2002; 129: 3185-3194.
176. Ieda M, Fukuda K, Hisaka Y et al. Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. J Clin Invest. 2004; 113: 876-884.
177. Clouthier DE, Hosoda K, Richardson JA et al. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development. 1998; 125: 813-824.